Innate Immunotherapeutics

Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.

The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.

On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS.

Email Alerts for:
ASX:IIL

Latest Media Releases

Innate Immunotherapeutics announces top-line results for trial of MIS416 in patients with secondary progressive multiple sclerosis

Summary: - Initial analysis of Phase 2B trial data on a total enrolled patient population basis show no clinically meaningful or statistically significant differences in measures of neuromuscular f…

Innate Immunotherapeutics, Financial Statements for the Year Ended 31 March 2017

Contents - Directors Report - Auditor’s Independence Declaration - Consolidated Statement of Profit or Loss and Other Comprehensive Income - Consolidated Statement of Financial Posit…

Innate Immunotherapeutics Announces FDA Clearance Received for MIS416 Investigational New Drug Application

Innate Immunotherapeutics Limited (ASX Code:IIL) is pleased to confirm it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) a…